15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Xenon Pharmaceuticals Inc, 10 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $55.00 to $97.00, a moderate spread. The average target of $74.80 sits 26% above the current $59.60. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.18 next quarter toward $-4.87 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Strong Buy
Strong Buy00%
Buy10100%
Hold00%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Xenon Pharmaceuticals Inc.
As of Sep, 10 of 10 firms rate XENE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
XENE EPS & revenue forecast
EPS · NEXT QUARTER
$-1.18
Range $-1.35 – $-0.85 · 14 analysts · -10% YoY
Next period, 14 analysts expect Xenon Pharmaceuticals Inc to earn $-1.18 a share (range $-1.35 – $-0.85), versus $-1.31 a year earlier. Full-year consensus is $-4.63, growing to $-4.87 the year after.
REVENUE · NEXT QUARTER
$788.4K
Range $0 – $7.6M · 14 analysts
Revenue is expected to reach $788.4K (range $0 – $7.6M). Full-year consensus is $1.2M, rising to $28.6M next year.
Top analysts covering Xenon Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on XENE.
#1
Yatin Suneja
Guggenheim · Rank #21
Buy
$90.00+51.0% to target
Overall win rate
53%
+ Follow
#2
Laura Chico
Wedbush · Rank #74
Buy
$63.00+5.7% to target
Overall win rate
44%
+ Follow
#3
Serge Belanger
Needham · Rank #105
Buy
$78.00+30.9% to target
Overall win rate
48%
+ Follow
#4
Jason Gerberry
B of A Securities · Rank #125
Buy
$77.00+29.2% to target
Overall win rate
46%
+ Follow
#5
Douglas Tsao
HC Wainwright & Co. · Rank #248
Buy
$74.00+24.2% to target
Overall win rate
35%
+ Follow
XENE stock forecast FAQ
What is XENE's average 12-month price target?+
The 10 analysts with a live target average $74.80 for Xenon Pharmaceuticals Inc over the next 12 months, ranging from a $97.00 high to a $55.00 low.
Is XENE stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 10 analyst ratings, 10 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for XENE?+
The Street-high target is $97.00 (Baird), and the Street-low is $55.00 (Chardan Capital). The average of all 10 active targets is $74.80.
How many Wall Street analysts cover XENE?+
10 analysts have an active rating on Xenon Pharmaceuticals Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering XENE?+
Among analysts who currently cover XENE, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Buy with a $90.00 target.
What is Xenon Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-1.18 per share (range $-1.35 – $-0.85) across 14 analysts. Full-year EPS is projected at $-4.63, rising to $-4.87 the following year.
How much revenue is Xenon Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $788.4K (range $0 – $7.6M). Full-year revenue is projected at $1.2M, growing to $28.6M next year.
Have analysts been upgrading or downgrading XENE lately?+
As of Sep, 10 of 10 firms rate XENE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their XENE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
